You are here

Pfizer

Pfizer's fast-growing Ibrance romps toward an early $5B payoff: analyst

Pfizer's fast-growing Ibrance romps toward an early $5B payoff: analyst

Fierce Pharma

Flag link:

Pfizer's fast-growing Ibrance romps toward an early $5B payoff: analyst

Pfizer's fast-growing Ibrance romps toward an early $5B payoff: analyst

Fierce Pharma

Flag link:

Pfizer hits a snag in bid to jump-start Sutent's flagging kidney cancer sales

Pfizer hits a snag in bid to jump-start Sutent's flagging kidney cancer sales

Fierce Pharma

Flag link:

Merck KGaA, Pfizer's cancer drug Bavencio gets EU nod

Merck KGaA, Pfizer's cancer drug Bavencio gets EU nod

Yahoo/Reuters

Merkel cell carcinoma

Flag link:

This squabble between two big drugmakers could have major implications for the U.S. health care system

This squabble between two big drugmakers could have major implications for the U.S. health care system

Marketwatch

Flag link:

3 Ways AI Is Changing Medicine

3 Ways AI Is Changing Medicine

Motley Fool

artificial intelligence

Gritstone Oncology

cancer immunotherapy

retinal blindness

Flag link:

Pfizer leads Big Pharma's emerging markets growth as GlaxoSmithKline, Eli Lilly lag

Pfizer leads Big Pharma's emerging markets growth as GlaxoSmithKline, Eli Lilly lag

Fierce Pharma

emerging markets

Flag link:

Pfizer files US lawsuit against Johnson & Johnson over "anticompetitive" practices related to Remicade biosimilar

Pfizer files US lawsuit against Johnson & Johnson over "anticompetitive" practices related to Remicade biosimilar

First Word Pharma

Flag link:

Remicade: A Case Study in How U.S. Pricing and Reimbursement Curb Adoption of Biosimilars

Remicade: A Case Study in How U.S. Pricing and Reimbursement Curb Adoption of Biosimilars

Drug Channels

Flag link:

New PhIII data in hand, Pfizer, Astellas hustle ahead in bid to expand US market for Xtandi

New PhIII data in hand, Pfizer, Astellas hustle ahead in bid to expand US market for Xtandi

Endpoints

clinical trials

prostate cancer

Flag link:

Prevnar 13 among blockbusters industry watchers peg as tribal licensing candidates

Prevnar 13 among blockbusters industry watchers peg as tribal licensing candidates

Fierce Pharma

Flag link:

AbbVie and Pfizer hover at top, J&J Stelara surges in August TV pharma ad spend

AbbVie and Pfizer hover at top, J&J Stelara surges in August TV pharma ad spend

Fierce Pharma

Flag link:

Allergan's Patent Loophole Could Be a Huge Gift for Pfizer

Allergan's Patent Loophole Could Be a Huge Gift for Pfizer

Motley Fool

Flag link:

#ESMO17: Eli Lilly sets the stage for a CDK 4/6 showdown with Pfizer, Novartis — but not exactly to its advantage

#ESMO17: Eli Lilly sets the stage for a CDK 4/6 showdown with Pfizer, Novartis — but not exactly to its advantage

Endpoints

Flag link:

FDA Form 483 for Celltrion May Offer a Glimpse Into Limited Uptake for Remicade Biosimilar

FDA Form 483 for Celltrion May Offer a Glimpse Into Limited Uptake for Remicade Biosimilar

RAPS.org

Flag link:

EpiPen Maker Neglected ‘Hundreds’ of Complaints About Defects

EpiPen Maker Neglected ‘Hundreds’ of Complaints About Defects

Bloomberg

Meridian Medical Technologies

Flag link:

Pfizer puts hemophilia spin on ultrapopular Minecraft to educate young patients

Pfizer puts hemophilia spin on ultrapopular Minecraft to educate young patients

Fierce Pharma

Flag link:

Allergan-Restasis Patent Battle Could Test Lawmakers' Resolve

Allergan-Restasis Patent Battle Could Test Lawmakers' Resolve

NY Shock Exchange

Teva Pharmaceutical

Flag link:

Key FDA Regulatory Events to Watch Out for in Sep 2017

Key FDA Regulatory Events to Watch Out for in Sep 2017

Yahoo/Zacks.com

PTC Therapeutics

Flag link:

FDA Approves Pfizer’s Mylotarg 7 Years After it was Pulled From the Market

FDA Approves Pfizer’s Mylotarg 7 Years After it was Pulled From the Market

RAPS.org

acute myeloid leukemia

Flag link: